Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3.

ABSTRACT: Treatment-induced neuroendocrine prostate cancer (NEPC) is a lethal subtype of castration-resistant prostate cancer. Using the ⁸⁹Zr-labeled delta-like ligand 3 (DLL3) targeting antibody SC16 (⁸⁹Zr-desferrioxamine [DFO]-SC16), we have developed a PET agent to noninvasively identify the presence of DLL3-positive NEPC lesions. Methods: Quantitative polymerase chain reaction and immunohistochemistry were used to compare relative levels of androgen receptor (AR)-regulated markers and the NEPC marker DLL3 in a panel of prostate cancer cell lines. PET imaging with ⁸⁹Zr-DFO-SC16, ⁶⁸Ga-PSMA-11, and ⁶⁸Ga-DOTATATE was performed on H660 NEPC-xenografted male nude mice. ⁸⁹Zr-DFO-SC16 uptake was corroborated by biodistribution stud

SUBMITTER: Korsen JA 

PROVIDER: S-EPMC9454466 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature